PropThink: Phase I/II Data On New Candidate Supports Higher Valuation For ARIA

[ACN Newswire] – By David MoskowitzWith Wall Street Analyst price targets on Ariad Pharmaceuticals (NASDAQ:ARIA) averaging $24.75 through this morning, new data for an early-stage pipeline candidate is causing price targets … more

View todays social media effects on ARIA

View the latest stocks trending across Twitter. Click to view dashboard